Fred T. Fiedorek - 18 Sep 2023 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Chief Medical Officer
Signature
/s/ Andrew Ashe, Attorney-in-Fact for Fred T. Fiedorek
Issuer symbol
VERV
Transactions as of
18 Sep 2023
Net transactions value
$0
Form type
4
Filing time
19 Sep 2023, 17:05:06 UTC
Next filing
16 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Award $0 +180,000 $0.000000 180,000 18 Sep 2023 Common Stock 180,000 $12.71 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on September 18, 2023. 25% of the shares underlying the option will vest on September 18, 2024, and the remainder are scheduled to vest in equal monthly installments thereafter until September 18, 2027.